Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialDavid A. Palma, Suresh Senan, Anand Swaminath et al.|The Lancet|2019Cited by 1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized TrialDavid A. Palma, Suresh Senan, Robert Olson et al.|Journal of Clinical Oncology|2020Cited by 1.2k
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C. Nichols, David A. Palma, Julie Theurer et al.|The Lancet Oncology|2019Cited by 459
Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialDavid A. Palma, Suresh Senan, Robert Olson et al.|BMC Cancer|2019Cited by 267
Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term OutcomesStephen Harrow, Suresh Senan, David A. Palma et al.|International Journal of Radiation Oncology*Biology*Physics|2022Cited by 201